Literature DB >> 33642763

Muscle Infiltrative Adult Multisystem Langerhans Cell Histiocytosis Detected on Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography - A Rare Case.

Sampanna Jung Rayamajhi1, Rajive Raj Shahi1, Sagar Maharjan1, Samir Sharma2, K C Sudhir Suman1.   

Abstract

Langerhans cell histiocytosis (LCH) is a disease of unknown pathogenesis characterized by the accumulation of Langerhans cells which show immunopositivity for S-100 and CD1a. LCH with skeletal muscle involvement has been rarely described in literature. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is an important tool in identifying the sites of involvement in LCH. We present a rare case of muscle invasive LCH where 18F-FDG PET/CT showed involvement of multiple other sites such as the liver, bones, bone marrow, and possibly the thyroid gland in our case. Further, the current case also shows that liver involvement by LCH (possibly fibrotic phase) can be negative on PET but show lesions on CT. Copyright:
© 2020 Indian Journal of Nuclear Medicine.

Entities:  

Keywords:  Fluorodeoxyglucose; Langerhans cell histiocytosis; positron emission tomography

Year:  2020        PMID: 33642763      PMCID: PMC7905280          DOI: 10.4103/ijnm.IJNM_88_20

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


Langerhans cell histiocytosis (LCH) is a disease of unknown pathogenesis characterized by the accumulation of Langerhans cells which show immunopositivity for S-100 and CD1a. The disease spectrum ranges from solitary organ involvement to multisystem disease. The incidence is higher in children as compared to adults. Skeletal muscle involvement is extremely rare, and only few cases have been described in literature.[123] Liver involvement is also considered rare in adults, a finding seen in extensive LCH and indicates bad prognosis.[4] We report a rare case of multisystemic adult LCH, presenting with multiple skeletal muscle lesions along with liver, bone, diffuse bone marrow, and possibly thyroid involvement. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is an established tool in identifying the extent of disease involvement in LCH, which could potentially change management.[56] Our patient was a 41-year-old female who initially presented with progressive discomfort of the right neck and shoulder region. Biopsy and immunohistochemistry of the right neck mass revealed immunopositivity for S-100 and CD1a. Subsequently, she underwent PET/CT from the vertex to the mid-thigh with intravenous contrast. There was extensive FDG-avid mass-like diffuse enlargement of the right subscapularis muscle along with focally FDG-avid areas involving the right anterior and middle scalene, infraspinatus, trapezius, and right intercostal muscles [Figure 1a-e]. Some of the FDG-avid foci in the muscles involved did not have changes on CT.
Figure 1

Maximum-intensity projection image (a), demonstrating fluorodeoxyglucose-avid lesions in the muscles, bones, thyroid gland, and diffusely increased fluorodeoxyglucose uptake in the bone marrow. Axial computed tomography (b) showing mass-like enlargement of the right subscapularis muscle and fused positron emission tomography/computed tomography (c) showing fluorodeoxyglucose-avid lesions in the right subscapularis muscle along with lytic changes in the scapula. Axial computed tomography (d) showing mass – slightly bulky right infraspinatus muscle and fused positron emission tomography/computed tomography (e) showing fluorodeoxyglucose-avid lesions in the right infraspinatus muscle

Maximum-intensity projection image (a), demonstrating fluorodeoxyglucose-avid lesions in the muscles, bones, thyroid gland, and diffusely increased fluorodeoxyglucose uptake in the bone marrow. Axial computed tomography (b) showing mass-like enlargement of the right subscapularis muscle and fused positron emission tomography/computed tomography (c) showing fluorodeoxyglucose-avid lesions in the right subscapularis muscle along with lytic changes in the scapula. Axial computed tomography (d) showing mass – slightly bulky right infraspinatus muscle and fused positron emission tomography/computed tomography (e) showing fluorodeoxyglucose-avid lesions in the right infraspinatus muscle There was lytic destruction of the right scapula [Figure 1d and e] and FDG-avid lytic lesions in the left femoral head and left scapula [Figure 2].
Figure 2

Axial computed tomography (a) and fused positron emission tomography/computed tomography (b) showing fluorodeoxyglucose-avid lytic lesion in the left femoral head and axial computed tomography (c) and fused positron emission tomography/computed tomography (d) showing lytic lesion in the left scapula

Axial computed tomography (a) and fused positron emission tomography/computed tomography (b) showing fluorodeoxyglucose-avid lytic lesion in the left femoral head and axial computed tomography (c) and fused positron emission tomography/computed tomography (d) showing lytic lesion in the left scapula Diffuse confluent nonenhancing hypodense lesions were seen in both the lobes of the liver, which were normal in size with some of the lesions appearing as band along the portal tracts [Figure 3], compatible with hepatic involvement of LCH.[4] Bilirubin, alanine transaminase, and aspartate transaminase were normal. Alkaline phosphatase was significantly elevated reaching 1492 (normal: 20–140 IU/L), representing severe cholestasis. Liver involvement in LCH is considered to progress through the following four histopathological stages: proliferative, granulomatous, xanthomatous, and fibrous phases.[7] The liver lesions in our case did not reveal high FDG uptake, which may possibly reflect advanced fibrotic phase [Figure 3b and d].
Figure 3

Axial computed tomography (a) showing avid confluent hypodense lesions without corresponding increased fluorodeoxyglucose uptake in the fused positron emission tomography/computed tomography (b). Coronal computed tomography (c) and fused positron emission tomography/computed tomography (d) showing these hypodense lesions along the portal tract

Axial computed tomography (a) showing avid confluent hypodense lesions without corresponding increased fluorodeoxyglucose uptake in the fused positron emission tomography/computed tomography (b). Coronal computed tomography (c) and fused positron emission tomography/computed tomography (d) showing these hypodense lesions along the portal tract The entire bone marrow showed diffusely increased FDG uptake, reflecting bone marrow involvement [Figure 1a], maximum-intensity projection image]. There was diffusely increased FDG uptake in the enlarged thyroid gland [Figure 1a] with ill-defined hypodense nodules, possibly be due to LCH involvement which is considered rare.[89] Interestingly, the lungs revealed no nodular or cystic changes. In addition, other known manifestations of LCH such as cutaneous lesions and CNS lesions were not seen. In conclusion, we describe a rare case of adult LCH involving the skeletal muscles, some of them without changes on CT but seen on fused PET/CT images. Second, the current case also shows that liver involvement by LCH (possibly fibrotic phase) can be negative on PET but show lesions on CT.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  9 in total

1.  MR imaging of infiltrative muscle involvement with Langerhans cell histiocytosis.

Authors:  David A May; Shaifali Kaushik; William J Frable
Journal:  Clin Imaging       Date:  2004 Jul-Aug       Impact factor: 1.605

Review 2.  18F-Fluorodeoxyglucose PET/CT in Langerhans cell histiocytosis: spectrum of manifestations.

Authors:  Krishan Kant Agarwal; Rachna Seth; Abhishek Behra; Manisha Jana; Rakesh Kumar
Journal:  Jpn J Radiol       Date:  2016-01-13       Impact factor: 2.374

3.  Role of 18F-FDG PET/CT in patients affected by Langerhans cell histiocytosis.

Authors:  Domenico Albano; Giovanni Bosio; Raffaele Giubbini; Francesco Bertagna
Journal:  Jpn J Radiol       Date:  2017-07-26       Impact factor: 2.374

4.  Unifocal Langerhans cell histiocytosis of the superior oblique muscle.

Authors:  Daniel Narayan; Edwin Figueira; Daniel Kearney; Penelope McKelvie; Garry Davis; Dinesh Selva
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 May-Jun       Impact factor: 1.746

5.  Langerhans' cell histiocytosis of the liver in adults.

Authors:  Meya Abdallah; Thierry Généreau; Jean Donadieu; Jean-François Emile; Olivier Chazouillères; Cécile Gaujoux-Viala; Jean Cabane
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-05-06       Impact factor: 2.947

6.  Diffuse Subcutaneous and Muscular Langerhans Cell Histiocytosis on FDG PET/CT.

Authors:  Dan Shao; Shuxia Wang
Journal:  Clin Nucl Med       Date:  2019-07       Impact factor: 7.794

Review 7.  Langerhans Cell Histiocytosis: Diagnosis on Thyroid Aspirate and Review of the Literature.

Authors:  Anjali Saqi; Adriana P Kuker; Susana A Ebner; John Ausiello; Vaidehi Jobanputra; Govind Bhagat; Tamar A Giorgadze
Journal:  Head Neck Pathol       Date:  2015-01-18

8.  Hepatic involvement of Langerhans cell histiocytosis in children--imaging findings of computed tomography, magnetic resonance imaging and magnetic resonance cholangiopancreatography.

Authors:  Yingyan Shi; Zhongwei Qiao; Chunmei Xia; Ying Gong; Haowei Yang; Guoping Li; Mier Pa
Journal:  Pediatr Radiol       Date:  2014-02-28

9.  18F-fluorodeoxyglucose positron emission tomography/computed tomography for primary thyroid langerhans histiocytosis: A case report and literature review.

Authors:  Qi Long; Wang Shaoyan; Wang Hui
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.